Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Dec;23(12):1657-64.
doi: 10.1038/ejhg.2015.32. Epub 2015 Mar 11.

The type of variants at the COL3A1 gene associates with the phenotype and severity of vascular Ehlers-Danlos syndrome

Michael Frank  1   2 , Juliette Albuisson  1   2   3 , Brigitte Ranque  2   3   4 , Lisa Golmard  1   3 , Jean-Michael Mazzella  1 , Laurence Bal-Theoleyre  5 , Anne-Laure Fauret  1   3 , Tristan Mirault  1   3 , Nicolas Denarié  1 , Elie Mousseaux  3   6 , Pierre Boutouyrie  2   3   7 , Jean-Noël Fiessinger  1   3 , Joseph Emmerich  1   3 , Emmanuel Messas  1   2   3 , Xavier Jeunemaitre  1   2   3
Affiliations

The type of variants at the COL3A1 gene associates with the phenotype and severity of vascular Ehlers-Danlos syndrome

Michael Frank et al. Eur J Hum Genet. 2015 Dec.

Abstract

Vascular Ehlers-Danlos syndrome (vEDS) is a rare and severe autosomal dominant disorder caused by variants at the COL3A1 gene. Clinical characteristics and course of disease of 215 molecularly proven patients (146 index cases and 69 relatives) were analysed. We found 126 distincts variants that were divided into five groups: (1) Glycine substitutions (n=71), (2) splice-site and in-frame insertions-deletions (n=36), (3) variants leading to haplo-insufficiency (n=7), (4) non-glycine missense variants within the triple helix (n=4 variants), and (5) non-glycine missense variants or in-frame insertions-deletions, in the N- or C-terminal part of the protein (n=8). Overall, our cohort confirmed the severity of the disease with a median age at first complication of 29 years (IQR 22-39), the most frequent being arterial (48%) and digestive (24%) ruptures. Groups 2 and 1 were significantly more severe than groups 3-5, with extreme median ages at first major complication of 23-47 years. Patients of groups 3-5 had a less typical phenotype and remarkably absence of digestive events. The distribution of glycine-replacing amino acids was strongly biased towards more destabilizing residues of the collagen assembly. Thus the natural course of vEDS and the clinical phenotype of patients are influenced by the type of COL3A1 variant. This study also confirms that patients with variants located in the C- and N-termini or leading to haplo-insufficiency have milder course of the disease and less prevalent diagnostic criteria. These findings may help refine diagnostic strategy, genetic counselling and clinical care.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Age of onset of the first major complication in 215 vEDS patients.
Figure 2
Figure 2
COL3A1 gene variants detected in 146 unrelated index cases with vEDS. Boxes represent exons of the COL3A1 gene (NG_007404.1) with colour code representing protein domains (yellow: N- and C-terminal domains, green: transition domains, blue: collagen helical domain). Glycine substitutions are presented on the left in a shortened, nonofficial nomenclature. The complete nomenclature of each variant can be found in the Supplementary Table S4, in which variants detected on the genomic but not on the cDNA sequence are indicated with parentheses, for example, p.(Gly324Ser). All of them have been reported in the Ehlers–Danlos Syndrome Variant Database (see Methods, Genetic analysis). Substitutions for other amino acids, splice-site variants and insertions/deletions are shown on the right. formula image indicates the variants found more than once in the index cases cohort; †indicates previously undescribed variants.
Figure 3
Figure 3
Age of onset of the first major complication as a function of type of COL3A1 variant in 215 patients with vEDS. Abbreviations: Splice/del/ins/dup, insertion, deletion, duplication or splice-site variant in the triple helix; Gly, Glycine; C/N domain, C-terminal or N-terminal domain of the protein; TH, triple helix.
Figure 4
Figure 4
Distribution of observed and expected AA residues substituting a Glycine residue. Expected substitutions are calculated from the corrected expected numbers as previously reported. Yates' chi-squared, P<0.001.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Pope FM, Narcisi P, Nicholls AC, Germaine D, Pals G, Richards AJ: COL3A1 mutations cause variable clinical phenotypes including acrogeria and vascular rupture. Br J Dermatol 1996; 135: 163–181. - PubMed
    1. Pepin M, Schwarze U, Superti-Furga A, Byers PH: Clinical and genetic features of Ehlers-Danlos syndrome type IV, the vascular type. N Engl J Med 2000; 342: 673–680. - PubMed
    1. Beighton P, De Paepe A, Steinmann B, Tsipouras P, Wenstrup RJ: Ehlers-Danlos syndromes: revised nosology, Villefranche, 1997. Ehlers-Danlos National Foundation (USA) and Ehlers-Danlos Support Group (UK). Am J Med Genet 1998; 77: 31–37. - PubMed
    1. Dalgleish R: The Human Collagen Mutation Database 1998. Nucleic Acids Res 1998; 26: 253–255. - PMC - PubMed
    1. Leistritz DF, Pepin MG, Schwarze U, Byers PH: COL3A1 haploinsufficiency results in a variety of Ehlers-Danlos syndrome type IV with delayed onset of complications and longer life expectancy. Genet Med 2011; 13: 717–722. - PubMed

Publication types